We use cookies on this website. By continuing to use this site without changing your cookie settings, you agree that you are happy to accept our cookies and for us to access these on your device. Find out more about how we use cookies and how to change your cookie settings.
Home > People > News > G6PD deficiency protects against severe malaria



G6PD deficiency protects against severe malaria

13/3/07. By the Public Library of Science

A study in Mali has found that glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with significant protection against severe, life-threatening malaria.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is known as 'favism' after the Italian word for broad beans (fava), which cause a classic reaction when eaten by people with G6PD deficiency. In males, who have only one X chromosome, mutations in the gene for G6PD on the X chromosome cause G6PD deficiency. Females who have mutations on both X chromosomes will also be deficient.

A case-control study in two populations in Mali has now found that G6PD (A-) deficiency protects hemizygous male children but not heterozygous female children against progression of malaria into life-threatening complications.

Scientists at the US National Institute of Allergy and Infectious Diseases and the University of Bamako, Mali, led by Thomas E Wellems, reported the findings in the journal 'PLoS Medicine'.

G6PD is an important enzyme in red blood cells (erythrocytes), the host cells for Plasmodium falciparum, the parasite that causes the most severe form of malaria. G6PD deficiency is associated with protection against malaria, notably in Africa where one form of G6PD deficiency (G6PD A-) is widespread.

In the two populations of more than 3000 children studied in rural Mali, where malaria is very common, G6PD deficiency in male and female children was associated with protection against severe, life-threatening malaria, but no effect was found in females who had just one abnormal gene. However, there was no significant difference in the numbers of parasites in the red blood cells of the various groups of children, indicating that the deficiency does not work by stopping parasites from infecting the children.

G6PD deficiency instead appears to mitigate disease processes set up by the parasitised cells in the bloodstream. The protection was confirmed by a combined analysis of these data and data from a previous study. Protection was most evident against cerebral malaria, the most frequent form of life-threatening malaria in these studies.

These results reignite the debate about the relationship between G6PD deficiency and protection against malaria. They are particularly relevant in populations such as the one studied where, as the authors note, because "virtually all young children experience episodes of malaria, such protective hemoglobinopathies and erythrocyte polymorphisms offer a tremendous survival benefit when they prevent progression of uncomplicated malaria".

Feature: Malaria versus the human genome

This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.

Adapted from a news release by the Public Library of Science.

References

Guindo A et al. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 2007;4(3):e66. Full text

Page of 2; 2/9/04

Document1

Share |
Wellcome Trust, Gibbs Building, 215 Euston Road, London NW1 2BE, UK T:+44 (0)20 7611 8888